⌘K
Loading ticker…
Ernexa Therapeutics Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Ernexa Therapeutics Inc. Common Stock (ERNA) has a 3-month relative strength percentile of 83 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 37. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 13.3%, relative volume 1.29×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
3m RS is 83, Market Stance is mixed at 47, A/D rating A
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ERNA is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -7.3% / -65.5%.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ERNA Jan avg: 18.12% median: 15.19% win: 75% σ: 25.62% n: 4 2022-10-18 → 2026-05-29 | ERNA Feb avg: -30.67% median: -19.74% win: 0% σ: 31.26% n: 4 2022-10-18 → 2026-05-29 | ERNA Mar avg: -21.43% median: -20.94% win: 25% σ: 62.31% n: 4 2022-10-18 → 2026-05-29 | ERNA Apr avg: 432.25% median: 0.50% win: 50% σ: 881.53% n: 4 2022-10-18 → 2026-05-29 | ERNA May avg: 42.92% median: 6.33% win: 75% σ: 97.00% n: 4 2022-10-18 → 2026-05-29 | ERNA Jun avg: -13.09% median: -3.68% win: 33% σ: 27.18% n: 3 2022-10-18 → 2026-05-29 (current) | ERNA Jul avg: 5.17% median: -1.09% win: 33% σ: 15.27% n: 3 2022-10-18 → 2026-05-29 | ERNA Aug avg: -10.90% median: -11.91% win: 33% σ: 12.76% n: 3 2022-10-18 → 2026-05-29 | ERNA Sep avg: -23.88% median: -17.67% win: 0% σ: 17.19% n: 3 2022-10-18 → 2026-05-29 | ERNA Oct avg: 1.41% median: -15.37% win: 50% σ: 50.29% n: 4 2022-10-18 → 2026-05-29 | ERNA Nov avg: -30.95% median: -32.18% win: 25% σ: 25.79% n: 4 2022-10-18 → 2026-05-29 | ERNA Dec avg: 13.99% median: -6.32% win: 25% σ: 58.26% n: 4 2022-10-18 → 2026-05-29 |